Biotech firm Imperagen secured £5 million ($6.7 million) in new funding, accelerating the development of technologies designed to make enzyme engineering “less costly” for industries from pharmaceuticals to agriculture. The investment round was led by PXN Ventures, with participation from IQ Capital and Northern Gritstone, channeling capital into a process aimed at increasing efficiency and reducing expenses for corporate entities.
The company, founded in 2021 by Manchester Institute of Biotechnology scientists Dr. Andrew Currin, Dr. Tim Eyes, and Dr. Andy Almond, has now accumulated £8.5 million ($11.42 million) in total funding. This capital infusion is directed at speeding up enzyme engineering, a process described as having a “domino effect” in making drug discovery “faster and more efficient” for pharmaceutical corporations. Enzymes are also critical in food, biofuels, and agriculture, sectors where cost reductions directly translate to increased profit margins for industrial producers.
Imperagen's approach replaces slower, “more physical, trial-and-error-focused” methods with a system built on quantum physics-based simulation, custom AI models, and robotic automation. This “closed-loop simulation” process, which uses robots to generate experimental data fed back to AI, aims to predict enzyme behavior and explore millions of mutations on a computer. The stated goal is to make enzyme development “faster, more reliable, and more commercially accessible,” enabling companies to bring “better bio-based products to market without the long timelines and uncertainty that have traditionally held the field back.” This technological shift, while framed as progress, inherently reduces the need for human labor in traditional, physical experimentation, potentially leading to wage suppression or displacement in the long term.
Accelerating Capital Accumulation
The fresh capital will be used to hire more AI specialists, fund research and development, expand experimental lab capabilities, and build a “go-to-market function” within the next two years. This strategic allocation of funds directly supports the expansion of Imperagen's capacity to serve industrial partners and secure further capital accumulation. Guy Levy-Yurista, who assumed the role of CEO, was brought in to scale the startup’s AI strategy, commercial models, and industrial partnerships, signaling a clear focus on market penetration and profit generation. His background in AI, life sciences, and enterprise technology aligns with the imperative to maximize commercial returns from scientific innovation.
The Promise of "Efficiency"
Levy-Yurista noted that current enzyme engineering processes, even with new AI-powered technologies, often “fail when put into practice on an industrial scale.” Imperagen's solution promises to overcome these hurdles, ensuring that technological advancements translate into tangible commercial benefits for adopting companies. The CEO's statement that “Ultimately, Imperagen hopes wider use of engineered enzymes will help industries reliably produce products that are cleaner, safer and better for people and the planet, while also making commercial sense for the companies that adopt them” reveals the underlying priority: environmental and social benefits are presented as secondary to “commercial sense.”
Commodification of Scientific Advance
The company's origin as a spin-out from the Manchester Institute of Biotechnology highlights the trend of public scientific research being privatized for commercial exploitation. While “experts in sustainability” are cited as looking to these technologies, the application remains firmly within the framework of industrial production and manufacturing, where the primary driver is profit. Competitors like Biomatter, Cradle Bio, and Absci also operate within this market, indicating a broader trend of capital investment in technologies that promise to streamline and cheapen industrial processes, further entrenching the existing economic order rather than fundamentally altering its extractive nature. The focus on “commercial accessibility” and “making commercial sense” underscores how scientific innovation is increasingly geared towards serving the interests of capital rather than collective human needs outside of a market framework.